Bristol Myers Squibb Canada (BMS) today announced Health Canada has granted conditional approval (NOC/c) for ABECMATM (idecabtagene vicleucel; ide-cel) as the first and only B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for adults with multiple myeloma (MM). ABECMATM is indicated for MM patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment.

Read the full press release